The annual meeting of the American Society for Clinical Oncology is prime time for biotechnology stocks. Most of the 300 drugs in the late stages of development are aimed at various forms of cancer, according to Needham & Co. analyst Mark Monane. Tiny biotechs flock to the cancer field, because cancer drugs are faster to develop than other pharmaceuticals--and because there are a mere 9,000 oncologists. Here are some of the most promising compounds that could lift the veil on data in front of the 20,000-plus people likely to attend the ASCO meeting in New Orleans.
